An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)

Trial Profile

An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Rocapuldencel-T (Primary) ; Sunitinib
  • Indications Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms ADAPT
  • Sponsors Argos Therapeutics Inc
  • Most Recent Events

    • 09 Aug 2017 According to an Argos Therapeutics media release, the FDA has agreed with the company's decision to continue this trial until 290 events have reached, the pre-specified number of events at which the analysis of overall survival, the primary endpoint, is to be conducted. The next planned analysis at 290 events is expected to occur during the first half of 2018. Interim results from this trial will be presented at the European Society of Medical Oncology (ESMO) annual meeting.
    • 10 Jun 2017 Biomarkers information updated
    • 06 Jun 2017 Planned End Date changed from 1 Apr 2016 to 1 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top